A German study suggesting lingering cardiac damage from COVID-19 has been corrected in JAMA Cardiology, but the conclusions stand.
Compounding pharmacy SCA Pharma pulled its heparin from hospitals nationwide over inaccurate labeling and inclusion of a potentially lethal preservative, benzyl alcohol. (FiercePharma)
Taking a selfie could be enough for coronary artery disease detection with a little help from artificial intelligence analysis. (European Heart Journal)
Two neurologists looked at the complexity of racism in stroke and suggested a framework to guide interventions aimed at reducing racial differences in health outcomes. (JAMA Neurology)
A “miniheart” created in the laboratory as a model of the fetal heart has all primary heart cell types and a functioning structure of chambers and vascular tissue, researchers reported in a manuscript posted to the medRxiv preprint server.
Most MIS-C associated with COVID-19 presents with cardiogenic shock, often with imaging findings of acute heart failure, a review noted in Radiology: Cardiothoracic Imaging.
Fitbit’s latest smartwatch gained temperature, stress, and ECG sensors for a wearable to compete with the Apple Watch. (CNET)
Most dialysis patients surveyed would want CPR for cardiac arrest. (JAMA Network Open)
Cardiac device implantation is the second most expensive procedure done at ambulatory surgery centers. (Becker’s ACS Review)
More evidence rolled in for less bystander CPR, slower EMS response, and reduced survival for out-of-hospital cardiac arrest, this time from the West Coast. (JACC: Clinical Electrophysiology)
The first 3D, full-body PET imaging device captures the dynamics of radioactive tracers in multiple organs at once for “a new window into human biology,” according to NIH Director Francis Collins, MD, PhD. Conventional imaging can capture the heart or the brain but not both at once.